Showing 4 posts of 4 posts found.


Positive CHMP opinion for BMS and Acceleron’s Reblozyl in transfusion-dependent anaemia sub-populations

May 1, 2020
Medical Communications, Sales and Marketing Acceleron, Bristol-Myers Squibb, EU, Reblozyl

Bristol Myers Squibb and Acceleron Pharma’s Reblozyl (luspatercept) has secured a positivr opinion from the European Medicines Agency’s Committee for Medicinal …

Celgene and Acceleron’s Reblozyl secures FDA approval for anaemia in beta thalassaemia

November 11, 2019
Sales and Marketing Acceleron, Celgene, Reblozyl, beta thalassaemia, pharma

The FDA has moved to authorise Celgene and Acceleron Pharma’s Reblozyl (luspatercept-aamt) in the treatment of anaemia associated with the …


Acceleron terminates drug candidate following facioscapulohumeral muscular dystrophy failure

September 17, 2019
Manufacturing and Production, Research and Development Acceleron, pharma, trial failure

Acceleron Pharma has seen its stock fall by almost 4% after it unveiled new Phase 2 data confirming that its …


Celgene and Acceleron’s blood disorder drug smashes endpoints at Phase 3

July 11, 2018
Research and Development Acceleron, Celgene, beta-thalassemia, luspatercept, pharma

Celgene and Acceleron have lifted the curtain on new Phase 3 data for their erythroid maturation agent (EMA) luspatercept, confirming …

Latest content